盐酸替罗非班对急性心肌梗死冠脉多支病变经皮冠状动脉介入术后疗效及安全性研究

doi:10.3969/j.issn.1006-6233.2017.10.026

Abstract
Figure/Table
References
Related Citation (12)

Download: PDF (1389 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the efficacy and safety of tirofiban in patients with acute myocardial infarction after percutaneous coronary intervention. Methods: 126 cases of acute myocardial infarction patients with multivessel coronary artery disease from emergency treatment in our hospital were selected, simple randomization, randomly divided into the control group and the experiment with 63 cases in each group according to the random number table method. Patients in the control group were treated with percutaneous coronary intervention; The treatment group was treated with Tirofiban Hydrochloride Injection on the basis of the control group.Two groups of patients in the postoperative unified symptomatic care.After treatment, the clinical therapeutic effect, postoperative complications, serum C reactive protein (CRP), serum creatine kinase isoenzyme (CK-MB), cardiac troponin T (cTnT) levels were compared between the two groups. Results: Data show that the total incidence rate of complications of the treatment group 11.11% was significantly lower than the control group 33.33% (P < 0.05); compared with before treatment, serum CRP, BNP, CK-MB and cTnT levels in patients decreased (P < 0.05), the serum CRP, BNP, CK-MB, cTnT levels were lower in experiment group than the control group (P < 0.05). Conclusion: The application of Tirofiban Hydrochloride Injection can effectively improve the operation effect of percutaneous coronary intervention in acute myocardial infarction patients with multivessel coronary artery disease, reduce the pain of patients, reduce the incidence of postoperative complications, control of complications have a positive effect on reducing the machine, and serum CRP, BNP, CK-MB and cTnT levels.

Key words： Acute myocardial infarction Coronary multivessel disease Coronary intervention tirofiban

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Jinyong

Cite this article:

YANG Jinyong. Study on the Efficacy and Safety of Tirofiban in Patients with Acute Myocardial| Infarction after Percutaneous Coronary Intervention[J]. 河北医学, 2017, 23(10): 1674-1677.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2017.10.026 OR http://www.hbyxzzs.cn/EN/Y2017/V23/I10/1674

[1]高润霖.急性心肌梗死诊断和治疗指南[J].中华心血管病杂志,2001,16(6):407~422.
[2] 杨艳敏,朱俊,谭慧琼,等.中国ST段抬高的急性心肌梗死临床特征及治疗现状[J].中华医学杂志,2005,85(31):2176~2182.
[3] 高润霖.从急性心肌梗死治疗指南看再灌注治疗策略的选择[J].中华心血管病杂志,2005,33(11):1061~1064.
[4] 黄从刚,李睿,左慧萍,等.急性心肌梗死危险因素和促发因素的青年人与中老年人暴露率比较[J].中华流行病学杂志,2007,28(3):282~285.
[5] 顾永群.影响急性心肌梗死患者近期预后的因素分析[J].中国基层医药,2009,16(9):1637~1638.
[6] 刘君,傅向华,马宁,等.急性心肌梗死经皮冠状动脉介入治疗后心肌灌注分级无再流现象对心室功能和收缩同步性的影响[J].中华心血管病杂志,2004,32(10):874~878.
[7] 陈韵岱,王长华.急性心肌梗死经皮冠状动脉介入治疗术后无复流的防治进展[J].中国循环杂志,2010,25(3):165~166.
[8] 田立群,巴英巴特,郑琼莉,等.替罗非班在急性心肌梗死经皮冠状动脉介入治疗中的应用[J].实用医学杂志,2008,24(3):442~444.
[9] 洪衡,王明生,王河,等.不同类型急性心肌梗死冠状动脉病变特点的观察[J].中国循环杂志,2007,22(3):187~190.
[10] 孙旻.中青年与老年人急性心肌梗死临床特点及冠状动脉病变比较[J].中国基层医药,2011,18(24):3367~3368.
[11] 高润霖,刘冰.经皮冠状动脉介入治疗指南[J].中华心血管病杂志,2002,37(12):707~718.
[12] 张红雨,王佩显,曹艳君,等.冠状动脉内注射替罗非班对急性心肌梗死患者介入治疗中无复流现象的疗效分析[J].第三军医大学学报,2010,27(20):25~29.
[13] 杨柳,韩英,张颖,等.替罗非班在冠状动脉介入手术治疗急性心肌梗死中的疗效及预后的影响[J].中国基层医药,2012,19(15):2337~2338.
[14] 王顺强.急性心肌梗死患者血清利钠肽水平与心肌梗死面积及预后的关系[J].中国基层医药,2013,20(10):1477~1478.
[15] 冯程娟,欧阳玲,杨松娣.联合检测hs-CRP、cTnI、Myo及CK-MB在急性心肌梗死诊断中的临床应用价值[J].中国现代医学杂志,2010,20(12):1881~1884.